HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CVS/Eckerd deal

This article was originally published in The Rose Sheet

Executive Summary

CVS will voluntarily refile its pre-merger notification and report form to comply with a request from the Federal Trade Commission, company announces May 14. The retailer's original April 16 submission prompted an informal request from FTC staff for additional information regarding the transaction, in which CVS will purchase about 1,260 Eckerd stores from J.C. Penney (1"The Rose Sheet" April 12, 2004, In Brief). The refiling allows FTC more time to "review the information submitted by CVS before the staff must determine what additional information, if any, it will formally request," according to CVS...

You may also be interested in...



Eckerd sale

J.C. Penney will sell its Eckerd drugstore chain to Brooks Pharmacy owner Jean Coutu and drugstore retailer CVS for $4.53 bil., company announces April 5. Jean Coutu will acquire 1,539 Eckerd stores and support facilities located in thirteen Northeast and mid-Atlantic states, as well as the Eckerd home office for $2.38 bil. Stores under Jean Coutu will retain the Eckerd name. CVS will acquire 1,260 Eckerd stores and support facilities located in southern states including Florida, Texas and Arizona, in addition to Eckerd's pharmacy benefits management and mail order business, for $2.15 bil. The firm plans to reopen the Eckerd stores under the CVS name. Transactions are expected to close by the end of the second quarter, subject to regulatory approvals...

Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line

The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.

Global Pharma Guidance Tracker – March 2024

Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS012147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel